Epstein-Barr virus serostatus: No difference despite aberrant patterns in athletes and control group

Medicine and Science in Sports and Exercise

Volumn 38, Issue 10, 2006, Pages 1782-1791

  Pottgiesser, Torben ^a   Wolfarth, Bernd ^a,b   Schumacher, Yorck Olaf ^a   Bauer, Georg ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Athletes; EBV; Exercise; IFA; Lineassay; Serology

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; PROTEIN ANTIBODY; PROTEIN P138 ANTIBODY; PROTEIN P18 ANTIBODY; PROTEIN P23 ANTIBODY; PROTEIN P54 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; ATHLETE; BINDING AFFINITY; CONTROLLED STUDY; CYCLING; ENDURANCE SPORT; EPSTEIN BARR VIRUS; EXERCISE; FEMALE; HUMAN; IMMUNOASSAY; INFECTION SENSITIVITY; MALE; SEROLOGY; SKIING; VIRUS INFECTION;

ACUTE DISEASE; ADULT; ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; DISEASE SUSCEPTIBILITY; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN G; MALE; PHYSICAL ENDURANCE; SPORTS;

EID: 33749478039     PISSN: 01959131     EISSN: None     Source Type: Journal    
DOI: 10.1249/01.mss.0000230122.91264.3f     Document Type: Article

References (28)

1. ANDERSSON, A., V. VETTER, L. KREUTZER, and G. BAUER. Avidities of IgG directed against viral capsid antigen or early antigen: useful markers for significant Epstein-Barr virus serology. J. Med. Virol. 43:238-244, 1994.
2. Deleted in proof.
3. BAUER, G. Simplicity through complexity: immunoblot with recombinant antigens as the new gold standard in Epstein-Barr virus serology. Clin. Lab. 47:223-230, 2001.
4. EVANS, A. S. Infectious mononucleosis and related syndromes. Am. J. Med. Sci. 276:325-339, 1978.
5. FLEISHER, G., W. HENLE, G. HENLE, E. T. LENNETTE, and R. J. BIGGAR. Primary infection with Epstein-Barr virus in infants in the United States: clinical and serologic observations. J. Infect. Dis. 139:553-558, 1979.
6. FLEISHER, G. R., M. COLLINS, and S. FAGER. Limitations of available tests for diagnosis of infectious mononucleosis. J. Clin. Microbiol. 17:619-624, 1983.
7. GLEESON, M., C. KOINA, R. L. CLANCY, et al. Epstein-Barr virus reactivation in elite swimmers. Int. J. Sports Med. 21(Suppl. 1): 83, 2000.
8. GLEESON, M., D. B. PYNE, J. P. AUSTIN, et al. Epstein-Barr virus reactivation and upper-respiratory illness in elite swimmers. Med. Sci. Sports Exerc. 34:411-417, 2002.
9. GRAY, J. J., J. CALDWELL, and M. SILLIS. The rapid serological diagnosis of infectious mononucleosis. J. Infect. 25:39-46, 1992.
10. HALLEE, T. J., A. S. EVANS, J. C. NIEDERMAN, C. M. BROOKS, and H. VOEGTLY. Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years. Yale J. Biol. Med. 47:182-195, 1974.
11. Deleted in proof.
12. HORWITZ, C. A., W. HENLE, G. HENLE, G. PENN, N. HOFFMAN, and P. C. WARD. Persistent falsely positive rapid tests for infectious mononucleosis. Report of five cases with four-six-year follow-up data. Am. J. Clin Pathol. 72:807-811, 1979.
13. JOAB, I., H. TRIKI, M. J. DE SAINT, M. PERRICAUDET, and J. C. NICOLAS. Detection of anti-Epstein-Barr virus trans-activator (ZEBRA) antibodies in sera from patients with human immunodeficiency virus. J. Infect. Dis. 163:53-56, 1991.
14. KAMPMANN, M., K. HENNINGER, and G. BAUER. Determination of antibodies directed specifically against Epstein-Barr virus nuclear antigen-1 (EBNA-1) by anticomplementary immunofluorescence (ACIF). Med. Microbiol. Letters 2:1-8, 1993.
15. LINDE, A. Diagnosis of Epstein-Barr virus-related diseases. Scand. J. Infect. Dis. Suppl. 100:83-88, 1996.
16. MACSWEEN, K. F., and D. H. CRAWPORD. Epstein-Barr virus-recent advances. Lancet Infect. Dis. 3:131-140, 2003.
17. MATHESON, B. A., S. M. CHISHOLM, and D. O. HO-YEN. Assessment of rapid ELISA test for detection of Epstein-Barr virus infection. J. Clin. Pathol. 43:691-693, 1990.
18. Deleted in proof.
19. NIEDERMAN, J. C., A. S. EVANS, L. SUBRAHMANYAN, and R. W. MCCOLLUM. Prevalence, incidence and persistence of EB virus antibody in young adults. N. Engl. J. Med. 282:361-365, 1970.
20. Deleted in proof.
21. Deleted in proof.
22. SCHILLINGER, M., M. KAMPMANN, K. HENNINGER, G. MURRAY, I. HANSELMANN, and G. BAUER. Variability of humoral immune response to acute Epstein-Barr virus (EBV) infection: evaluation of the significance of serological markers. Med. Microbiol. Letters 2:296-303, 1993.
23. SEVIER, T. L. Infectious disease in athletes. Med. Clin. North Am. 78:389-412, 1994.
24. TEDESCHI, R., J. DILLNER, and P. DE PAOLI. Antibody responses to defined epitopes in the Epstein-Barr virus BZLF1-encoded transactivator protein among human immunodeficiency virus-infected patients. Clin. Diagn. Lab. Immunol. 3:363-364, 1996.
25. VETTER, V., L. KREUTZER, and G. BAUER. Differentiation of primary from secondary anti-EBNA-1-negative cases by determination of avidity of VCA-IgG. Clin. Diag. Viro. 2:29-39, 1994.
26. VIDRIH, J. A., R. P. WALENSKY, P. E. SAX, and K. A. FREEDBERG. Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection. Am. J. Med. 111:192-194,2001.
27. WOLTER, T., C. GASSMANN, V. VETTER, and G. BAUER. Avidity determination: utilization of a basic immunological mechanims allows to improve serological diagnosis of infections. Clin. Lab. 43:125-135, 1997.
28. YAMAUCHI, Y., Y. TACHIBAND, A. MAEDA, et al. Evaluation of antibodies to the Epstein-Barr virus immediate early gene product ZEBRA by a new enzyme-linked immunosorbent assay. Intervirology 41:278-284, 1998.